Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 161.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,845 shares of the life sciences company’s stock after purchasing an additional 4,846 shares during the period. Intech Investment Management LLC’s holdings in Illumina were worth $1,023,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Empowered Funds LLC increased its holdings in Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after buying an additional 66 shares during the period. Caprock Group LLC boosted its holdings in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after purchasing an additional 83 shares during the last quarter. UMB Bank n.a. grew its position in Illumina by 7.0% during the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after purchasing an additional 88 shares during the period. Integrated Advisors Network LLC raised its stake in shares of Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after buying an additional 90 shares during the last quarter. Finally, Moors & Cabot Inc. lifted its holdings in shares of Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after buying an additional 95 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Trading Up 1.0 %

Shares of Illumina stock opened at $144.36 on Thursday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock’s 50 day simple moving average is $141.42 and its 200-day simple moving average is $125.53. The stock has a market cap of $22.90 billion, a P/E ratio of -14.49 and a beta of 1.13. Illumina, Inc. has a 1-year low of $93.51 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the prior year, the business earned $0.33 EPS. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. Analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Leerink Partners lifted their price target on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Royal Bank of Canada lifted their target price on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Canaccord Genuity Group increased their price target on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $120.00 to $154.00 in a report on Friday, August 16th. Finally, Robert W. Baird increased their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.